UY35748A - Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple - Google Patents
Terapia combinada con laquinimod para el tratamiento de la esclerosis múltipleInfo
- Publication number
- UY35748A UY35748A UY0001035748A UY35748A UY35748A UY 35748 A UY35748 A UY 35748A UY 0001035748 A UY0001035748 A UY 0001035748A UY 35748 A UY35748 A UY 35748A UY 35748 A UY35748 A UY 35748A
- Authority
- UY
- Uruguay
- Prior art keywords
- laquinimod
- treatment
- multiple sclerosis
- combined therapy
- cis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883698P | 2013-09-27 | 2013-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35748A true UY35748A (es) | 2015-04-30 |
Family
ID=52740749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035748A UY35748A (es) | 2013-09-27 | 2014-09-26 | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20150094332A1 (https=) |
| EP (1) | EP3049075A4 (https=) |
| JP (1) | JP2016533323A (https=) |
| KR (1) | KR20160085757A (https=) |
| CN (1) | CN105848653A (https=) |
| AR (1) | AR097792A1 (https=) |
| AU (1) | AU2014342917A1 (https=) |
| BR (1) | BR112016006582A2 (https=) |
| CA (1) | CA2925493A1 (https=) |
| EA (1) | EA201690673A1 (https=) |
| IL (1) | IL244620A0 (https=) |
| MX (1) | MX2016003763A (https=) |
| SG (1) | SG11201602175VA (https=) |
| TW (1) | TW201601722A (https=) |
| UY (1) | UY35748A (https=) |
| WO (1) | WO2015065628A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| EP1915334A2 (en) * | 2005-07-07 | 2008-04-30 | Aditech Pharma AB | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| KR20150065951A (ko) * | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| JP2012530701A (ja) * | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| IN2014MN00333A (https=) * | 2011-07-28 | 2015-09-25 | Teva Pharma |
-
2014
- 2014-09-26 US US14/498,024 patent/US20150094332A1/en not_active Abandoned
- 2014-09-26 CA CA2925493A patent/CA2925493A1/en active Pending
- 2014-09-26 JP JP2016516547A patent/JP2016533323A/ja not_active Withdrawn
- 2014-09-26 UY UY0001035748A patent/UY35748A/es not_active Application Discontinuation
- 2014-09-26 CN CN201480053575.8A patent/CN105848653A/zh active Pending
- 2014-09-26 KR KR1020167011039A patent/KR20160085757A/ko not_active Withdrawn
- 2014-09-26 MX MX2016003763A patent/MX2016003763A/es unknown
- 2014-09-26 BR BR112016006582A patent/BR112016006582A2/pt not_active IP Right Cessation
- 2014-09-26 WO PCT/US2014/057705 patent/WO2015065628A2/en not_active Ceased
- 2014-09-26 TW TW103133660A patent/TW201601722A/zh unknown
- 2014-09-26 AR ARP140103582A patent/AR097792A1/es unknown
- 2014-09-26 AU AU2014342917A patent/AU2014342917A1/en not_active Abandoned
- 2014-09-26 SG SG11201602175VA patent/SG11201602175VA/en unknown
- 2014-09-26 EA EA201690673A patent/EA201690673A1/ru unknown
- 2014-09-26 EP EP14857795.0A patent/EP3049075A4/en not_active Withdrawn
-
2016
- 2016-03-15 IL IL244620A patent/IL244620A0/en unknown
- 2016-05-31 US US15/169,139 patent/US20160271094A1/en not_active Abandoned
-
2017
- 2017-07-06 US US15/643,214 patent/US20170304253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160085757A (ko) | 2016-07-18 |
| AR097792A1 (es) | 2016-04-13 |
| CN105848653A (zh) | 2016-08-10 |
| SG11201602175VA (en) | 2016-04-28 |
| EP3049075A4 (en) | 2017-05-03 |
| EP3049075A2 (en) | 2016-08-03 |
| IL244620A0 (en) | 2016-04-21 |
| JP2016533323A (ja) | 2016-10-27 |
| US20160271094A1 (en) | 2016-09-22 |
| AU2014342917A1 (en) | 2016-04-21 |
| EA201690673A1 (ru) | 2016-08-31 |
| BR112016006582A2 (pt) | 2017-08-01 |
| WO2015065628A3 (en) | 2015-10-29 |
| MX2016003763A (es) | 2016-10-28 |
| US20170304253A1 (en) | 2017-10-26 |
| TW201601722A (zh) | 2016-01-16 |
| CA2925493A1 (en) | 2015-05-07 |
| US20150094332A1 (en) | 2015-04-02 |
| WO2015065628A2 (en) | 2015-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| EA201301240A1 (ru) | Полиморфная форма бензоата линаглиптина | |
| EA201690753A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| BR112015022538A2 (pt) | terapia de indução de rituximab seguida por terapia de acetato de glatirâmero | |
| MX2016001446A (es) | Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos. | |
| MX381776B (es) | Formulacion acuosa que comprende paracetamol e ibuprofeno. | |
| NZ708821A (en) | Lfa-1 inhibitor formulations | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| NZ735777A (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| PY1330684A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| UY35748A (es) | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple | |
| BR112015028884A2 (pt) | tratamento ou prevenção de depressão utilizando mentol e/ou icilina | |
| CO7170180A2 (es) | Composición farmacéutica inyectable de dexketoprofeno y tramadol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211207 |